Uridine-derived ribose fuels glucose-restricted pancreatic cancer.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
21
06
2021
accepted:
12
04
2023
medline:
2
6
2023
pubmed:
18
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to therapy
Identifiants
pubmed: 37198494
doi: 10.1038/s41586-023-06073-w
pii: 10.1038/s41586-023-06073-w
pmc: PMC10232363
mid: NIHMS1902848
doi:
Substances chimiques
Ribose
681HV46001
Uridine
WHI7HQ7H85
Glucose
IY9XDZ35W2
UPP1 protein, human
EC 2.4.2.3
KRAS protein, human
0
Uridine Phosphorylase
EC 2.4.2.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-158Subventions
Organisme : BLRD VA
ID : IK2 BX005875
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA234222
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA237421
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA262209
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Singhi, A. D., Koay, E. J., Chari, S. T. & Maitra, A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 156, 2024–2040 (2019).
pubmed: 30721664
doi: 10.1053/j.gastro.2019.01.259
Wood, L. D., Canto, M. I., Jaffee, E. M. & Simeone, D. M. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology 163, 386–402.e1 (2022).
pubmed: 35398344
doi: 10.1053/j.gastro.2022.03.056
Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527–540 (2020).
pubmed: 32398706
pmcid: 7442729
doi: 10.1038/s41571-020-0363-5
DuFort, C. C., DelGiorno, K. E. & Hingorani, S. R. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology 150, 1545–1557.e2 (2016).
pubmed: 27072672
doi: 10.1053/j.gastro.2016.03.040
Encarnación-Rosado, J. & Kimmelman, A. C. Harnessing metabolic dependencies in pancreatic cancers. Nat. Rev. Gastroenterol. Hepatol. 18, 482–492 (2021).
pubmed: 33742165
pmcid: 8249349
doi: 10.1038/s41575-021-00431-7
Halbrook, C. J. & Lyssiotis, C. A. Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell 31, 5–19 (2017).
pubmed: 28073003
doi: 10.1016/j.ccell.2016.12.006
Helms, E., Onate, M. K. & Sherman, M. H. Fibroblast heterogeneity in the pancreatic tumor microenvironment. Cancer Discov. 10, 648–656 (2020).
pubmed: 32014869
pmcid: 8261791
doi: 10.1158/2159-8290.CD-19-1353
Koong, A. C. et al. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. 48, 919–922 (2000).
doi: 10.1016/S0360-3016(00)00803-8
Beatty, G. L., Werba, G., Lyssiotis, C. A. & Simeone, D. M. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev. 35, 940–962 (2021).
pubmed: 34117095
pmcid: 8247606
doi: 10.1101/gad.348523.121
Kamphorst, J. J. et al. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res. 75, 544–553 (2015).
pubmed: 25644265
pmcid: 4316379
doi: 10.1158/0008-5472.CAN-14-2211
Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633–637 (2013).
pubmed: 23665962
pmcid: 3810415
doi: 10.1038/nature12138
Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25, 717–729 (2011).
pubmed: 21406549
pmcid: 3070934
doi: 10.1101/gad.2016111
Zhao, H. et al. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. eLife 5, e10250 (2016).
pubmed: 26920219
pmcid: 4841778
doi: 10.7554/eLife.10250
Halbrook, C. J. et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. 29, 1390–1399.e6 (2019).
pubmed: 30827862
pmcid: 6602533
doi: 10.1016/j.cmet.2019.02.001
Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016).
pubmed: 27509858
pmcid: 5228623
doi: 10.1038/nature19084
Kim, P. K. et al. Hyaluronic acid fuels pancreatic cancer cell growth. eLife 10, e62645 (2021).
pubmed: 34951587
pmcid: 8730721
doi: 10.7554/eLife.62645
Klijn, C. et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33, 306–312 (2015).
pubmed: 25485619
doi: 10.1038/nbt.3080
Possemato, R. et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346–350 (2011).
pubmed: 21760589
pmcid: 3353325
doi: 10.1038/nature10350
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
pubmed: 22460905
pmcid: 3320027
doi: 10.1038/nature11003
Choi, J. W. et al. Uridine protects cortical neurons from glucose deprivation-induced death: possible role of uridine phosphorylase. J. Neurotrauma 25, 695–707 (2008).
pubmed: 18457515
doi: 10.1089/neu.2007.0409
Choi, J. W. et al. Uridine prevents the glucose deprivation-induced death of immunostimulated astrocytes via the action of uridine phosphorylase. Neurosci. Res. 56, 111–118 (2006).
pubmed: 16839635
doi: 10.1016/j.neures.2006.06.004
Wice, B. M., Reitzer, L. J. & Kennell, D. The continuous growth of vertebrate cells in the absence of sugar. J. Biol. Chem. 256, 7812–7819 (1981).
pubmed: 6790526
doi: 10.1016/S0021-9258(18)43351-0
Geiger, A. & Yamasaki, S. Cytidine and uridine requirement of the brain. J. Neurochem. 1, 93–100 (1956).
pubmed: 13398823
doi: 10.1111/j.1471-4159.1956.tb12059.x
Löffler, M., Wenzel, A. & Schneider, F. Cytokinetic studies on the switch from glucose to uridine metabolism, and vice versa, of Ehrlich ascites tumour cells in vitro. Cell Prolif. 20, 181–190 (1987).
doi: 10.1111/j.1365-2184.1987.tb01097.x
Linker, W., Löffler, M. & Schneider, F. Uridine, but not cytidine can sustain growth of Ehrlich ascites tumor cells in glucose-deprived medium with altered proliferation kinetics. Eur. J. Cell Biol. 36, 176–181 (1985).
pubmed: 3996430
King, M. P. & Attardi, G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246, 500–503 (1989).
pubmed: 2814477
doi: 10.1126/science.2814477
Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).
pubmed: 23535601
pmcid: 3656466
doi: 10.1038/nature12040
Lee, H.-J., Kremer, D. M., Sajjakulnukit, P., Zhang, L. & Lyssiotis, C. A. A large-scale analysis of targeted metabolomics data from heterogeneous biological samples provides insights into metabolite dynamics. Metabolomics 15, 103 (2019).
pubmed: 31289941
pmcid: 6616221
doi: 10.1007/s11306-019-1564-8
Yuan, M. et al. Ex vivo and in vivo stable isotope labelling of central carbon metabolism and related pathways with analysis by LC–MS/MS. Nat. Protoc. 14, 313–330 (2019).
pubmed: 30683937
pmcid: 7382369
doi: 10.1038/s41596-018-0102-x
Sullivan, M. R. et al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 8, e44235 (2019).
pubmed: 30990168
pmcid: 6510537
doi: 10.7554/eLife.44235
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. & DePinho, R. A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218–1249 (2006).
pubmed: 16702400
doi: 10.1101/gad.1415606
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M. & Lyssiotis, C. A. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat. Rev. Cancer 21, 510–525 (2021).
pubmed: 34244683
doi: 10.1038/s41568-021-00375-9
Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 122, 639–653 (2012).
pubmed: 22232209
pmcid: 3266788
doi: 10.1172/JCI59227
Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
pubmed: 22541435
pmcid: 3472002
doi: 10.1016/j.cell.2012.01.058
Candido, J. B. et al. CSF1R
pubmed: 29719257
pmcid: 5946718
doi: 10.1016/j.celrep.2018.03.131
Zhang, Y. et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66, 124–136 (2017).
pubmed: 27402485
doi: 10.1136/gutjnl-2016-312078
Zhang, D., Cao, D., Russell, R. & Pizzorno, G. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Res. 61, 6899–6905 (2001).
pubmed: 11559567
Dalin, S. et al. Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 79, 5723–5733 (2019).
pubmed: 31484670
pmcid: 7357734
doi: 10.1158/0008-5472.CAN-19-0960
Tabata, S. et al. Thymidine catabolism as a metabolic strategy for cancer survival. Cell Rep. 19, 1313–1321 (2017).
pubmed: 28514652
doi: 10.1016/j.celrep.2017.04.061
Wang, T. et al. Inosine is an alternative carbon source for CD8
pubmed: 32694789
pmcid: 7371628
doi: 10.1038/s42255-020-0219-4
Jurkowitz, M. S., Litsky, M. L., Browning, M. J. & Hohl, C. M. Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J. Neurochem. 71, 535–548 (1998).
Litsky, M. L., Hohl, C. M., Lucas, J. H. & Jurkowitz, M. S. Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Brain Res. 821, 426–432 (1999).
pubmed: 10064830
doi: 10.1016/S0006-8993(99)01086-0
Skinner. O. S. et al. Salvage of ribose from uridine or RNA supports glycolysis in nutrient-limiting conditions. Nat. Metab. https://doi.org/10.1038/s42255-023-00774-2 (2023).
Puleo, F. et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155, 1999–2013.e3 (2018).
pubmed: 30165049
doi: 10.1053/j.gastro.2018.08.033
Vaas, L. A. I. et al. opm: an R package for analysing OmniLog(R) phenotype microarray data. Bioinformatics 29, 1823–1824 (2013).
pubmed: 23740744
doi: 10.1093/bioinformatics/btt291
Ran, F. A. et al. Genome engineering using the CRISPR–Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
pubmed: 24157548
pmcid: 3969860
doi: 10.1038/nprot.2013.143
Kerk, S. A. et al. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. eLife 11, e73245 (2022).
pubmed: 35815941
pmcid: 9328765
doi: 10.7554/eLife.73245
Yi, Z. et al. KDM6A regulates cell plasticity and pancreatic cancer progression by noncanonical activin pathway. Cell. Mol. Gastroenterol. Hepatol. 13, 643–667 (2022).
pubmed: 34583087
doi: 10.1016/j.jcmgh.2021.09.014
Scales, M. K. et al. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. PLoS Genet. 18, e1010315 (2022).
pubmed: 35867772
pmcid: 9348714
doi: 10.1371/journal.pgen.1010315
Uhlén, M. et al. Tissue-based map of the human proteome. Science 347, 1260419 (2015).
pubmed: 25613900
doi: 10.1126/science.1260419
Barrett, T. et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 41, D991–D995 (2013).
pubmed: 23193258
doi: 10.1093/nar/gks1193
Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675–678 (2020).
pubmed: 32444850
pmcid: 7386072
doi: 10.1038/s41587-020-0546-8
Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576.e16 (2017).
pubmed: 28753430
pmcid: 5667678
doi: 10.1016/j.cell.2017.06.010
Gearing, L. J. et al. CiiiDER: A tool for predicting and analysing transcription factor binding sites. PLoS ONE 14, e0215495 (2019).
pubmed: 31483836
pmcid: 6726224
doi: 10.1371/journal.pone.0215495
Steele, N. G. et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat. Cancer 1, 1097–1112 (2020).
pubmed: 34296197
pmcid: 8294470
doi: 10.1038/s43018-020-00121-4